A small biotech company entering clinical phase secures the path for its lead gene therapy candidate's by designing a well-thought and value creating outsourcing strategy.
Larka is handling around 100 sourcing and external supply projects per year to help biotech and Big Pharma companies select optimal economical, technical and value-creating solutions across the whole value chain.
A bio-CDMO implements Operational Excellence and improves its efficiency in manufacturing and analytical operations, leading to CapEx needs reduction and margins improvements.
A mid-size gene therapy CDMO boosts its bottom line and stay ahead of the competition by implementing a smart price strategy based on the value created for customers.
A small recombinant protein CDMO leverages research marketing insights and data science to build a powerful Marketing Strategy boosting their Sales effectiveness and driving profitable growth.
A small CDMO in biologics' early development improves its customers' experience and increases its sales performance by implementing well-designed Inbound Marketing and Digital Strategy in its operations.
A mid-size CDMO in recombinant proteins and gene therapies stands out from its competitors and wins clients and talents by developing a distinctive and compelling brand.
An industrial player in the biopharma market with multiple businesses maximizes its returns by rethinking and implementing an optimal portfolio strategy.
A big industrial player of the biopharma industry acquires an equipment supplier and develops the right organizational design to capture the value promised to investors and employees.
A bioprocess equipment supplier transforms its annual strategy review into an agile process fostering creative thinking and giving strategic planning a more valuable role in the development and execution of the business strategies.
Thanks to our Integrated Due Diligence solution - combining Commercial, Technical and Operational Due Diligences -, a Private Equity firm gets a full appreciation of the capabilities, synergies and risks involved and a full-potential vision for the business.
An industrial player partners with an investment firm to build a new CDMO in the gene therapy and recombinant protein field through multiple acquisitions.
Thanks to a well-thought divestment process plan, a Big Pharma company makes a successful business unit separation and creates value for its portfolio of assets.